MedTrace Logo

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells.

PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.

Conditions

  • Stage IV Melanoma
  • Stage IV Renal Cell Cancer
  • Recurrent Renal Cell Cancer
  • Recurrent Melanoma

Interventions

DRUG

flt3 ligand

DRUG

gp100 antigen

DRUG

MART-1 antigen

DRUG

Montanide ISA-51

DRUG

tyrosinase peptide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Patrick Hwu · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019396 on ClinicalTrials.gov